Search Within

Hematology-Oncology Fellows

  1. "Adult Leukemia"
Formats
  1. Meeting Abstract (85)
  2. Journal Article (73)
  3. Research Letter (18)
  4. Review (16)
  5. Editorial (10)
  6. Correspondence (2)
Groups
  1. Adult Leukemia (204)
  2. Center for Hematologic Malignancies (204)
  3. Department of Medicine (204)
  4. Hematologic Malignancies, Division of (204)
  5. Graduate Medical Education (149)
  6. GME, Medicine (147)

More Groups

People
  1. Eytan Stein (58)
  2. Aaron Goldberg (48)
  3. Jan Bewersdorf (47)
  4. Martin Tallman (46)
  5. Jae Park (41)
  6. Andriy Derkach (35)

More People

Years
  1. 2025 (15)
  2. 2024 (34)
  3. 2023 (40)
  4. 2022 (34)
  5. 2021 (33)
  6. 2020 (27)

More Years

Publications
  1. Blood (76)
  2. Leukemia and Lymphoma (11)
  3. Blood Advances (9)
  4. Haematologica (8)
  5. Journal of Clinical Oncology (8)
  6. American Journal of Hematology (7)

More Publications

Publishers
  1. American Society of Hematology (87)
  2. Nature Publishing Group (19)
  3. Elsevier Inc. (13)
  4. Taylor & Francis Group (11)
  5. John Wiley & Sons (10)
  6. American Society of Clinical Oncology (9)

More Publishers

Results (204)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiation therapy for patients with diffuse large B cell Richter's syndrome of CLL
    Meeting Abstract

    Sacchi De Camargo Correia, G.; Imber, B. S.; Hajj, C.; Thompson, M. C.; Mato, A. R.; Yahalom, J.; Roeker, L. E.
    Blood (2021)

    Fulltext@MSK | Save
  • Multicenter analysis of treatment and outcomes for patient with TP53 mutated AML in the era of novel therapies; Significant impact of allogeneic stem cell transplantation on survival
    Meeting Abstract

    Badar, T.; Litzow, M. R.; Shallis, R. M.; Bewersdorf, J. P.; Saliba, A.; sacchi De Camargo Correia, G.; Stahl, M.; Goldberg, A. D.; Atallah, E. L.; Foran, J. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
    Editorial

    Bewersdorf, J. P.; Stone, R. M.; Tallman, M. S.; Stahl, M.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
    Journal Article

    Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation - A systematic review and meta-analysis
    Review

    Bewersdorf, J. P.; Allen, C.; Mirza, A. S.; Grimshaw, A. A.; Giri, S.; Podoltsev, N. A.; Gowda, L.; Cho, C.; Tallman, M. S.; Zeidan, A. M.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Bridging chemotherapy prior to CD19-specific CAR T-cell therapy in children/young adults with relapsed/refractory acute lymphoblastic leukemia
    Meeting Abstract

    Shahid, S.; Ramaswamy, K.; Flynn, J.; Mauguen, A.; Boelens, J. J.; Forlenza, C.; Kernan, N.; Shukla, N.; Steinherz, P.; Sulis, M. L.; more...
    Pediatric Blood and Cancer (2021)

    Fulltext@MSK | Save
  • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E.
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
    Research Letter

    Perica, K.; Flynn, J.; Curran, K. J.; Rivere, I.; Wang, X.; Senechal, B.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies
    Research Letter

    Roeker, L. E.; Eyre, T. A.; Thompson, M. C.; Lamanna, N.; Coltoff, A. R.; Davids, M. S.; Baker, P. O.; Leslie, L.; Rogers, K. A.; Allan, J. N.; more...
    Blood (2021)

    Fulltext@MSK | Save